Advertisement

Clinical and Experimental Medicine

, Volume 18, Issue 4, pp 555–562 | Cite as

A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung

  • Junna Hou
  • Lihua Xing
  • Yufen Yuan
Original Article
  • 54 Downloads

Abstract

The aim was to investigate the clinicopathological characteristics, diagnosis, and prognosis of sarcomatoid carcinoma of the lung. We reviewed 114 cases of sarcomatoid carcinoma of the lung in patients that were admitted to the First Affiliated Hospital of Zhengzhou University and Anyang Tumor Hospital from January 2009 to March 2018. We analyzed the clinical characteristics, immunohistochemical profiles, treatments, and overall survival of the patients. The patient population included 88 men and 26 women. Median patient age was 65 years (range 37–88 years), and the gender ratio (M/F) was 3.4:1. Median survival was 3.5 months (range 0.5–60 months). Univariate analysis showed that tumor location, tumor size, M stage, TNM stage, chemotherapy, and surgery were all prognostic factors for survival (P < 0.05). We found that T stage, surgery, and chemotherapy were independent prognostic factors for sarcomatoid carcinoma (P < 0.05). Pulmonary sarcomatoid carcinoma is a rare tumor with a poor prognosis. Patients with smaller T stage, complete resection, and chemotherapy exhibited a better prognosis. Early diagnosis and early treatment are important to improve the prognosis of these patients.

Keywords

Sarcomatoid carcinoma Clinical pathology Lung cancer Survival analysis Treatment response 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Chang YL, Lee YC, Shih JY, et al. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer. 2001;34(1):91–7.CrossRefGoogle Scholar
  2. 2.
    Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(1 Suppl):191–202.CrossRefGoogle Scholar
  3. 3.
    Travis WD, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: Oxford University Press; 2004.Google Scholar
  4. 4.
    Martin LW, Correa AM, Ordonez NG, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thoracic Surg. 2007;84(3):973–80.CrossRefGoogle Scholar
  5. 5.
    Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2016.Google Scholar
  6. 6.
    Eisenhauera EA, Therasseb P, Bogaertsc J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefGoogle Scholar
  7. 7.
    Moore T. Carcinosarcoma of the lung. Surgery. 1961;50:886–93.PubMedGoogle Scholar
  8. 8.
    Mochizuki T, Ishii G, Nagai K, et al. Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol. 2008;32(11):1727–35.  https://doi.org/10.1097/PAS.0b013e3181804302.CrossRefPubMedGoogle Scholar
  9. 9.
    Nakajima M, Kasai T, Hashimoto H, et al. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer. 1999;86(4):608–16.CrossRefGoogle Scholar
  10. 10.
    Linping Gu, Yunhua Xu, Chen Zhiwei, et al. Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. Biomed Pharmacother. 2015;76:134–40.CrossRefGoogle Scholar
  11. 11.
    Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;8(2):103–20.CrossRefGoogle Scholar
  12. 12.
    Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol. 1996;20(3):277–85.CrossRefGoogle Scholar
  13. 13.
    Ro JY, Chen JL, Lee JS, et al. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer. 1992;69(2):376–86.CrossRefGoogle Scholar
  14. 14.
    Torenbeek R, Hermsen MA, Meijer GA, et al. Analysis by comparative genomic hybridization of epithelial and spindle cell components in sarcomatoid carcinoma and carcinosarcoma: histogenetic aspects. J Pathol. 1999;189(3):338–43.CrossRefGoogle Scholar
  15. 15.
    Boland JM, Mansfield AS, Roden AC. Pulmonary sarcomatoid carcinoma—a new hope. Ann Oncol. 2017;28(7):1417–8.CrossRefGoogle Scholar
  16. 16.
    Kou CJ, Kandpal RP. Differential expression patterns of Eph receptors and Ephrin ligands in human cancers. Biomed Res Int. 2018;28(2018):7390104.Google Scholar
  17. 17.
    Chaft JE, Sima CS, Ginsberg MS, et al. Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung. J Thoracic Oncol. 2012;7(9):1400–5.CrossRefGoogle Scholar
  18. 18.
    Nakagomi Takahiro, Goto Taichiro, Hirotsu Yosuke, et al. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget. 2018;9(12):10635–49.CrossRefGoogle Scholar
  19. 19.
    Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212–8.CrossRefGoogle Scholar
  20. 20.
    Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.CrossRefGoogle Scholar
  21. 21.
    Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.CrossRefGoogle Scholar
  22. 22.
    Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–74.CrossRefGoogle Scholar
  23. 23.
    Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.CrossRefGoogle Scholar
  24. 24.
    Yuki T, Sakuma T, Ohbayashi C, et al. Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg. 2007;134(2):399–404.CrossRefGoogle Scholar
  25. 25.
    Suda K, Sato K, Shimizu S, et al. Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. Biomed Res Int. 2014;2014:645681.CrossRefGoogle Scholar
  26. 26.
    Chang Yih-Leong, Lee Yung-Chie, Shih Jin-Yuan, et al. Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma. Lung Cancer. 2001;34(1):91–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Pulmonary MedicineThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of PathologyAnyang Tumor HospitalAnyangChina

Personalised recommendations